Effective respiratory management of asthma and COPD and the environmental impacts of inhalers.
作者信息
Usmani Omar S, Levy Mark L
机构信息
National Heart and Lung Institute, Imperial College London and Royal Brompton Hospital and St Mary's Hospital, London, UK.
Locum General Practitioner, London, UK.
出版信息
NPJ Prim Care Respir Med. 2023 Jul 1;33(1):24. doi: 10.1038/s41533-023-00346-7.
Abstract
摘要
相似文献
1
Effective respiratory management of asthma and COPD and the environmental impacts of inhalers.
NPJ Prim Care Respir Med. 2023 Jul 1;33(1):24. doi: 10.1038/s41533-023-00346-7.
2
Guidance on handheld inhalers in asthma and COPD guidelines: An update.
Respir Med. 2015 Dec;109(12):1592-3. doi: 10.1016/j.rmed.2015.10.017. Epub 2015 Nov 3.
3
Respiratory inhalers and the environment.
Aust J Gen Pract. 2022 Dec;51(12):929-934. doi: 10.31128/AJGP-08-22-6536.
4
Environmental impact of inhalers for respiratory diseases: decreasing the carbon footprint while preserving patient-tailored treatment.
BMJ Open Respir Res. 2020 Mar;7(1). doi: 10.1136/bmjresp-2020-000571.
5
Asthma and chronic obstructive pulmonary disease inhalers: Techniques for proper use.
Allergy Asthma Proc. 2016 Jul;37(4):279-90. doi: 10.2500/aap.2016.37.3954.
6
Impact of Single Combination Inhaler versus Multiple Inhalers to Deliver the Same Medications for Patients with Asthma or COPD: A Systematic Literature Review.
Int J Chron Obstruct Pulmon Dis. 2020 Feb 26;15:417-438. doi: 10.2147/COPD.S234823. eCollection 2020.
7
Misuse and/or treatment delivery failure of inhalers among patients with asthma or COPD: A review and recommendations for the conduct of future research.
Respir Med. 2017 Aug;129:98-116. doi: 10.1016/j.rmed.2017.05.004. Epub 2017 May 15.
8
Climate Change and Inhaler Selection in Patients With Respiratory Disease.
Chest. 2024 Mar;165(3):503-506. doi: 10.1016/j.chest.2023.09.025.
9
Carbon footprint impact of the choice of inhalers for asthma and COPD.
Thorax. 2020 Jan;75(1):82-84. doi: 10.1136/thoraxjnl-2019-213744. Epub 2019 Nov 7.
10
Nebulized corticosteroids in asthma and COPD. An Italian appraisal.
Respir Care. 2012 Jul;57(7):1161-74. doi: 10.4187/respcare.01414. Epub 2012 Jan 23.
引用本文的文献
1
Comparing the CO emissions of metered dose inhalers and dry powder inhalers: a cross-sectional environmental impact analysis of asthma and COPD therapies in South Tyrol, Italy.
BMJ Open Respir Res. 2025 Jun 27;12(1):e002977. doi: 10.1136/bmjresp-2024-002977.
2
Driving Sustainability in Asthma and COPD Management: Preventative Models and Green Prescribing in a Rural Primary Care Practice in England.
J Prim Care Community Health. 2025 Jan-Dec;16:21501319251334217. doi: 10.1177/21501319251334217. Epub 2025 Apr 21.
3
Optimising Asthma Self-Management: Preliminary Validation of an Arabic Version of the Inhaler Technique Questionnaire.
Pharmacy (Basel). 2025 Jan 20;13(1):6. doi: 10.3390/pharmacy13010006.
4
Impact of Triple Inhaler Therapy on COPD Patients with Non-Small Cell Lung Cancer After Radical Surgery: A Single-Centre Retrospective Analysis.
J Clin Med. 2025 Jan 3;14(1):249. doi: 10.3390/jcm14010249.
本文引用的文献
1
Understanding the feasibility and environmental effectiveness of a pilot postal inhaler recovery and recycling scheme.
NPJ Prim Care Respir Med. 2023 Jan 21;33(1):5. doi: 10.1038/s41533-023-00327-w.
2
Effectiveness of individualized inhaler technique training on low adherence (LowAd) in ambulatory patients with COPD and asthma.
NPJ Prim Care Respir Med. 2022 Jan 10;32(1):1. doi: 10.1038/s41533-021-00262-8.
3
Reducing carbon footprint of inhalers: analysis of climate and clinical implications of different scenarios in five European countries.
BMJ Open Respir Res. 2021 Dec;8(1). doi: 10.1136/bmjresp-2021-001071.
4
Health-care Resource Requirements and Potential Financial Consequences of an Environmentally Driven Switch in Respiratory Inhaler Use in England.
J Health Econ Outcomes Res. 2021 Sep 23;8(2):46-54. doi: 10.36469/001c.26113. eCollection 2021.
5
Health care's response to climate change: a carbon footprint assessment of the NHS in England.
Lancet Planet Health. 2021 Feb;5(2):e84-e92. doi: 10.1016/S2542-5196(20)30271-0.
6
The Climate is Changing for Metered-Dose Inhalers and Action is Needed.
Drug Des Devel Ther. 2020 Jul 29;14:3043-3055. doi: 10.2147/DDDT.S262141. eCollection 2020.
7
Minimising the environmental impact of inhaled therapies: problems with policy on low carbon inhalers.
Eur Respir J. 2020 Feb 27;55(2). doi: 10.1183/13993003.00048-2020. Print 2020 Feb.
8
Overuse of short-acting β-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme.
Eur Respir J. 2020 Apr 16;55(4). doi: 10.1183/13993003.01872-2019. Print 2020 Apr.
9
SABINA: global programme to evaluate prescriptions and clinical outcomes related to short-acting β-agonist use in asthma.
Eur Respir J. 2020 Feb 12;55(2). doi: 10.1183/13993003.01858-2019. Print 2020 Feb.
10
Carbon footprint impact of the choice of inhalers for asthma and COPD.
Thorax. 2020 Jan;75(1):82-84. doi: 10.1136/thoraxjnl-2019-213744. Epub 2019 Nov 7.
Zotero 插件